Ayala Pharmaceuticals Inc (STU:FAD)
€ 0.01 -0.04 (-80%) Market Cap: 788,000.00 Enterprise Value: 3.88 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

Advaxis Inc and Ayala Pharmaceuticals Inc M&A Call Transcript

Oct 19, 2022 / 12:00PM GMT
Operator

Greetings. Welcome to the Ayala Pharmaceuticals and Advaxis Enter Into Merger Agreement Conference Call. (Operator Instructions) Please note that this conference is being recorded.

At this time, I will hand the conference over to Tim McCarthy of LifeSci Advisors. Tim, you may now begin.

Timothy McCarthy
LifeSci Advisors, LLC - MD & Relationship Manager

Thank you, operator, and good morning, everyone, and thank you for joining us.

Before we begin formal remarks, let me remind you that some of the information in today's news release and on this conference call contains forward-looking statements within the meaning of the U.S. Property (sic) [Private] Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, the anticipated benefits of the proposed transaction between Ayala Pharmaceuticals, Inc. and Advaxis, Inc; the anticipated impact of the proposed transaction on the combined company's business and future financial and operating results; the expected amount and timing of synergies from the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot